Pharmacologic Issues in Treating Hypertension in CKD

Advances in Chronic Kidney Disease

Volumn 18, Issue 1, 2011, Pages 42-47

  Sica, Domenic A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Aldosterone receptor antagonsists (ARAs); Angiotensin receptor blockers (ARBs); Angiotensin converting enzyme (ACE) inhibitors; Cardiovascular (CV); Hypertension

Indexed keywords

ALDOSTERONE ANTAGONIST; ALISKIREN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENALAPRIL MALEATE; EPLERENONE; FOSINOPRIL; LISINOPRIL; LOSARTAN; METOLAZONE; MINOXIDIL; MOEXIPRIL; PERINDOPRIL; QUINAPRIL; RAMIPRIL; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TIMOLOL; TRANDOLAPRIL; UNINDEXED DRUG; VERAPAMIL;

ACUTE KIDNEY FAILURE; ADJUVANT THERAPY; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; DIURETIC THERAPY; DRUG ACCUMULATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG ELIMINATION; HEART LEFT VENTRICLE OVERLOAD; HUMAN; HYPERTENSION; KIDNEY FUNCTION; PERIPHERAL EDEMA; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; DIURETICS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; RECEPTORS, ALDOSTERONE; RENAL INSUFFICIENCY, CHRONIC; RENIN;

EID: 78651105846     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2010.11.003     Document Type: Review

References (42)

1. Sica D., Carl D. Pathologic basis and treatment considerations in chronic kidney disease-related hypertension. Semin Nephrol 2005, 25:246-251.
2. Lewis J.B. Blood pressure control in chronic kidney disease: is less really more?. J Am Soc Nephrol 2010, 21:1086-1092.
3. Appel L.J., Wright J.T., Greene T., et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010, 363:918-929.
4. Kidney Disease Outcomes Quality Initiative (K/DOQI) K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004, 43(suppl 1):S1-S290.
5. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
6. Bakris G.L., Weir M.R., Shanifar S., et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003, 163:1555-1565.
7. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
8. Berl T., Hunsicker L.G., Lewis J.B., et al. Cardiovascular outcomes in the irbesartan diabetic nephropathy trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003, 138:542-549.
9. Rahman M., Pressel S., Davis B.R., et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med 2006, 144:172-180.
10. Sica D.A. Metolazone and its role in edema management. Congest Heart Fail 2003, 9:100-105.
11. Mitch W.E., Wilcox C.S. Disorders of body fluids, sodium and potassium in chronic renal failure. Am J Med 1982, 72:536-550.
12. Calhoun D.A., Jones D., Textor S., et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008, 51:1403-1419.
13. Sica D.A. The risks and benefits of aldosterone antagonists. Curr Heart Fail Rep 2005, 2:65-71.
14. Santos J., Planas R., Pardo A., et al. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. J Hepatol 2003, 39:187-192.
15. Sica D.A. Eplerenone: a new aldosterone receptor antagonist: are the FDA's restrictions appropriate. J Clin Hypertens (Greenwich) 2002, 4:441-445.
16. Sica D.A. Hyperkalemia risk in chronic kidney disease: deterrent to the use of aldosterone receptor antagonism or not. Hypertension 2009, 53:749-750.
17. Sica D.A. Kinetics of angiotensin converting enzyme inhibitors in renal failure. J Cardiovasc Pharmacol 1992, 20(suppl 10):S13-S20.
18. Haas M., Leko-Mohr Z., Erler C., Mayer G. Antiproteinuric versus antihypertensive effects of high-dose ACE inhibitor therapy. Am J Kidney Dis 2002, 40:458-463.
19. Tobe S.W., Dai M.O. Outcomes of antiproteinuric RAAS blockade: high-dose compared with dual therapy. Curr Hypertens Rep 2009, 11:345-353.
20. Ruggenenti P., Mise N., Pisoni R., et al. Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. Circulation 2003, 107:586-592.
21. Schoolwerth A., Sica D.A., Ballermann B.J., Wilcox C.S. Renal considerations in angiotensin converting enzyme inhibitor therapy. Circulation 2001, 104:1985-1991.
22. Sica D.A. Renal handling of angiotensin receptor blockers: clinical relevance. Curr Hypertens Rep 2003, 5:337-339.
23. Bakris G.L., Siomos M., Richardson D., et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int 2000, 58:2084-2092.
24. Vaidyanathan S., Bigler H., Yeh C., et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin Pharmacokinet 2007, 46:661-675.
25. Parving H.H., Persson F., Lewis J.B., Lewis E.J., Hollenberg N.K. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358:2433-2446. AVOID Study Investigators.
26. Sica D.A., Gehr T.W. Calcium-channel blockers and end-stage renal disease: pharmacokinetic and pharmacodynamic considerations. Curr Opin Nephrol Hypertens 2003, 12:123-131.
27. Chrysant S.G., Chrysant C., Trus J., Hitchcock A. Antihypertensive effectiveness of amlodipine in combination with hydrochlorothiazide. Am J Hypertens 1989, 2:537-541.
28. Sica D.A. Current concepts of pharmacotherapy in hypertension: combination calcium channel blocker therapy in the treatment of hypertension. J Clin Hypertens (Greenwich) 2001, 3:322-327.
29. Agodoa L.Y., Appel L., Bakris G.L., et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001, 285:2719-2728.
30. Bakris G.L., Weir M.R., Secic M., et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004, 65:1991-2002.
31. Frishman W.H., Alwarshetty M. Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines. Clin Pharmacokinet 2002, 41:505-516.
32. McCullough P.A., Sandberg K.R., Borzak S., et al. Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. Am Heart J 2002, 144:226-232.
33. Bakris G.L. Role for beta-blockers in the management of diabetic kidney disease. Am J Hypertens 2003, 16(9 Pt 2):7S-12S.
34. Schlaich M.P., Socratous F., Hennebry S., et al. Sympathetic activation in chronic renal failure. J Am Soc Nephrol 2009, 20:933-939.
35. Lowenthal D.T., Affrime M.B., Meyer A., et al. Pharmacokinetics and pharmacodynamics of clonidine in varying states of renal function. Chest 1983, 83(suppl 2):386-390.
36. Sica D.A., Grubbs R. Transdermal clonidine: therapeutic considerations. J Clin Hypertens (Greenwich) 2005, 7:558-562.
37. Ross E.A., Pittman T.B., Koo L.C. Strategy for the treatment of noncompliant hypertensive hemodialysis patients. Int J Artif Organs 2002, 25:1061-1065.
38. Byrd B.F., Collins H.W., Primm R.K. Risk factors for severe bradycardia during oral clonidine therapy for hypertension. Arch Intern Med 1988, 148:729-733.
39. Black H.R., Sollins J.S., Garofalo J.L. The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: a randomized, placebo-controlled study. Am J Hypertens 2000, 13(5 Pt 1):468-474.
40. Yasuda G., Hasegawa K., Kuji T., et al. Effects of doxazosin on ambulatory blood pressure and sympathetic nervous activity in hypertensive Type 2 diabetic patients with overt nephropathy. Diabet Med 2005, 22:1394-1400.
41. Mori Y., Matsubara H., Nose A., et al. Safety and availability of doxazosin in treating hypertensive patients with chronic renal failure. Hypertens Res 2001, 24:359-363.
42. Bryson C.L., Psaty B.M. A review of the adverse effects of peripheral alpha-1 antagonists in hypertension therapy. Curr Control Trials Cardiovasc Med 2002, 3:1-7.